These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
398 related items for PubMed ID: 19152436
1. Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia. Pedrazzoli P, Rosti G, Secondino S, Siena S. Cancer; 2009 Mar 15; 115(6):1169-73. PubMed ID: 19152436 [Abstract] [Full Text] [Related]
2. Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia. Schiavetto I, Pedrazzoli P, Basilico V, Siena S. Chemotherapy; 2008 Mar 15; 54(6):417-20. PubMed ID: 18824846 [Abstract] [Full Text] [Related]
8. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Montera MW, Rassi S, Clausell N. J Card Fail; 2007 Feb 15; 13(1):14-7. PubMed ID: 17338998 [Abstract] [Full Text] [Related]
9. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Henry DH, Dahl NV, Auerbach MA. Am J Hematol; 2012 Mar 15; 87(3):308-10. PubMed ID: 22262486 [Abstract] [Full Text] [Related]
10. [Iron protein-succinylate in the treatment of adult iron-deficiency anemia]. Pujol Farriols R, Anglada Oriol M, Formiga Pérez F, Fernández-Sabe N, Mitjavila Vileró F, Vidaller Palacín A. An Med Interna; 2002 Dec 15; 19(12):651-2. PubMed ID: 12593038 [No Abstract] [Full Text] [Related]
11. Correcting iron-restricted erythropoiesis and improving anemia in patients on hemodialysis: practical tips that can make a difference. Easom A. Nephrol Nurs J; 2009 Dec 15; 36(5):529-37, 553. PubMed ID: 19856814 [Abstract] [Full Text] [Related]
12. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure, part III.2: treatment of anaemia with iron. Vaage-Nilsen O. Nephrol Dial Transplant; 2005 Jul 15; 20(7):1512-3; author reply 1513-4. PubMed ID: 15967789 [No Abstract] [Full Text] [Related]
13. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective. Luporsi E, Mahi L, Morre C, Wernli J, de Pouvourville G, Bugat R. J Med Econ; 2012 Jul 15; 15(2):225-32. PubMed ID: 22077267 [Abstract] [Full Text] [Related]
15. Role of iron deficiency and anemia in cardio-renal syndromes. Attanasio P, Ronco C, Anker SD, Cicoira M, von Haehling S. Semin Nephrol; 2012 Jan 15; 32(1):57-62. PubMed ID: 22365163 [Abstract] [Full Text] [Related]
17. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia? Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR. Adv Chronic Kidney Dis; 2009 Mar 15; 16(2):143-51. PubMed ID: 19233073 [Abstract] [Full Text] [Related]
19. Hepcidin for clinicians. Young B, Zaritsky J. Clin J Am Soc Nephrol; 2009 Aug 15; 4(8):1384-7. PubMed ID: 19556376 [Abstract] [Full Text] [Related]
20. Triumph and tragedy: anemia management in chronic kidney disease. Novak JE, Szczech LA. Curr Opin Nephrol Hypertens; 2008 Nov 15; 17(6):580-8. PubMed ID: 18941350 [Abstract] [Full Text] [Related] Page: [Next] [New Search]